Other adverse events: any serious adverse event ‐ short and long term · patients with schizophrenia
It is very uncertain whether PERPHENAZINE changes other adverse events: any serious adverse event ‐ short and long term compared with ANY ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Service use and hospitalisation: admission ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Global state: Change over time ‐ no better or deterioration ‐ short and medium term as defined in each study · patients with schizophrenia
It is very uncertain whether PERPHENAZINE changes global state: Change over time ‐ no better or deterioration ‐ short… compared with ANY ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Mental state: State ‐ 'no effect' BPRS score reduction · patients with schizophrenia
It is very uncertain whether PERPHENAZINE changes mental state: State ‐ 'no effect' BPRS score reduction compared with ANY ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
> 50% reduction in depressive symptoms · schizophrenia
Lithium showed no clear difference in clinically significant response on depressive symptoms at least 50%… compared with antipsychotics (low certainty).
1 finding from 1 review
Clinically significant response on manic symptoms at least 50% Bech‐Rafaelsen improvement · schizophrenia
Lithium showed no clear difference in clinically significant response on manic symptoms at least 50%… compared with antipsychotics (low certainty).
1 finding from 1 review
Clinically significant response on positive symptoms at least 50% MS improvement · schizophrenia
Lithium may leads to lower clinically significant response on positive symptoms at least 50% MS… compared with antipsychotics (low certainty).
1 finding from 1 review
Kidney dysfunction outcome not available in any study · schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Thyroid dysfunction outcome not available in any study · schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Response to treatment clinically relevant response as defined by the authors · schizophrenia
Lithium showed no clear difference in response to treatment clinically relevant response as defined by the… compared with antipsychotics (low certainty).
1 finding from 1 review
Acceptability ‐ total dropouts · schizophrenia
It is very uncertain whether lithium changes acceptability of treatment leaving early due to any reason compared with antipsychotics (very low certainty).
1 finding from 1 review
Clinical response: mental state ‐ relapse ‐ medium term Relapse rate · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response: global state ‐ no clinical improvement ‐ short term Rates of improvement · patients with schizophrenia or related psychoses
FLUPENTHIXOL DECANOATE showed no clear difference in clinical response: global state ‐ no clinical improvement ‐ short… compared with OTHER DEPOT ANTIPSYCHOTICS (low certainty).
1 finding from 1 review
Hospital admissions · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early ‐ short/medium term Rate of attrition · patients with schizophrenia or related psychoses
FLUPENTHIXOL DECANOATE showed no clear difference in leaving the study early ‐ short/medium term Rate of attrition compared with OTHER DEPOT ANTIPSYCHOTICS (low certainty).
1 finding from 1 review
Adverse effects: general ‐ movement disorders ‐ requiring anticholinergic medication ‐ short/medium term Numbers requiring anticholinergic medication · patients with schizophrenia or related psychoses
FLUPENTHIXOL DECANOATE showed no clear difference in adverse effects: general ‐ movement disorders ‐ requiring… compared with OTHER DEPOT ANTIPSYCHOTICS (low certainty).
1 finding from 1 review
Economic outcomes ‐ long term ‐ not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: Response ‐ proxy outcome ‐ mental state: 1. General ‐ average score (Brief Psychiatric Rating Scale by over 24 weeks · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: no improvement ‐ medium termAs defined in each study · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found